Australian patients with the most common form of lymphoma will for the first time have access to affordable, at-home treatment options after the federal subsidisation of an injectable immunotherapy.

Adoptive Cell Transfer (ACT) includes a class of immunotherapy approaches to treat cancer.  This procedure focuses on a ...

Galapagos reported promising results from ATALANTA-1 study show 100% ORR/CR for relapsed Mantle Cell Lymphoma. Click for GLPG ...

New data published in The Journal of Immunology uncovered the role of Plasmodium falciparum infection (malaria) in the ...

ALX Oncology (ALXO) announced “encouraging” data from an ongoing Phase 1/2 investigator-sponsored trial of the company’s lead clinical ...

New data published in The Journal of Immunology has revealed the role of Plasmodium falciparum infection (malaria) in the ...

The CRISPR company is laying off about a third of its employees and stopping work on an experimental lupus treatment in a bid ...

Researchers in South Korea have proposed a novel cancer immunotherapy approach that could complement existing CAR-T (Chimeric Antigen Receptor T-cell) treatments.

AACR's achievement awards and lectureships recognize innovation in basic, translational, clinical, and epidemiological cancer research.

Liso-Cel is a type of CAR T-cell therapy — a revolutionary approach that uses a patient's own immune cells to fight cancer.

"When the first BTK inhibitor got approved by the FDA for other conditions, we all saw that follicular lymphoma should be the ...